Innovative technologies and integrated methodologies in the field of mitochondrial DNA (mtDNA) and its gene expression

EU has granted the new Doctoral Network “MITGEST” (Quality Control of the Mitochondrial Gene Expression System in Health and Disease) with 2.6 million euros of funding under the Marie Sklodowska-Curie Actions. The project coordinated by the University of Udine will recruit 11 PhD candidates to produce advances and innovation in the field of mitochondrial dysfunction and its many disease manifestations through a multidisciplinary training programme. MITGEST network of seven research institutions and two companies enables close cooperation between industry and academia and provides doctoral candidates with a sustainable environment to grow their careers through innovative research. MITGEST aims to educate a young generation of scientists with the scientific and transferable skills needed to tackle the many challenges of the highly complex and integrated roles in cellular metabolism and disease in which mitochondria participate.

Mitochondria disfunction

Mitochondria are considered the powerhouses of the cell, generating the majority of the chemical energy needed to power the cell’s biochemical reactions. Dysfunction of the mitochondria is at the root of many human disorders that can present at any age with a wide range of overlapping clinical phenotypes. Mitochondrial dysfunction has also been implicated in common conditions such as cancer and ageing. Still, the understanding of the links between mitochondrial dysfunction and disease pathophysiology is limited. MITGEST’s findings will provide critical information for the development of effective treatments and disease biomarkers that represent an urgent unmet need in the biomedical area of mitochondrial dysfunction.

Recruitment for the 11 PhD positions will start in September 2022.